13 February 2023 | News
To provide hemp-based wellness by introducing clinically tested and research backed medical cannabis products
image credit- getty images
Bombay Hemp Company (BOHECO), a Mumbai-based industrial hemp and medical cannabis startup, recently marked 10 years of providing research-led and innovation backed hemp-based wellness to consumers. On occasion of their 10th year since inception, the brand reaffirmed their commitment towards patients with the launch of a range of next generation, clinically trialed cannabis leaf based products targeted towards various chronic pain and mental health conditions.
The clinical study for arthritis (Osteoarthrosis), conducted among the age group of 30-75 years, was done in line with global assessments and measured on the Western Ontario and McMaster Universities Arthritis Index (WOMAC) and Visual Analog Scale (VAS). It revealed that external application of GLIDE+ was efficacious in providing significant improvement in pain relief and joint motility with 4 and 8 weeks of regular usage with no adverse side effects reported.
Similarly, the clinical trial for PRISTINE showed marked improvement in EASI (Eczema Area and Severity Index) scores and symptoms of itchiness, dryness and rashes for patients suffering from eczema after regular application of the product.
“The recent success of the cultivation of industrial hemp with legally permissible limits of Tetrahydrocannabinol (THC) is bolstered by the release of the clinical trial reports for GLIDE+ and PRISTINE. The preliminary results indicate medical cannabis’ immense efficacy in managing both pain and skin conditions,” said Chirag Tekchandaney, Co-founder & CEO, Bombay Hemp Company (BOHECO).
Looking ahead, the startup plans to refocus on patient centricity through the medical cannabis lens – specifically for pain, mental health and stress. To this end, they have high quality and clinically tested pain management and mental health wellness products in the pipeline that will hit the shelves in the coming quarter.
BOHECO is also exporting hemp-based products to several international destinations like South Korea, Malaysia and the Middle East among others, in addition to working with governments to develop policy frameworks towards favourable regulatory pathways for the clinical trials & prescription based distribution of Cannabis based medicines.